{"id":221,"kind":"story","title":"AI新薬パイロット95％が失敗する市場でバイオドが選ばれた","url":"https://www.venturesquare.net/1069039/","host":"venturesquare.net","by":"mrlatte","score":1,"comments":0,"time":"2026-03-27T12:46:52.000Z","origin":"archive","language":{"source":"ko","reading":"ja","translated":true},"summary":["バイオドは中小ベンチャー企業庁の「超格差1000+」に選ばれ、最大6億ウォンの支援金を確保した。","株式を手放さずに研究を続けられる点で、初期のバイオチームには喜ばしい知らせだ。","新薬開発のどの作業を改善し、支援金がなくなるまでにどの実験を終えるかを決めておくと、次の投資家に見せる内容もはるかに明確になる。"],"discussion":"https://startupxo.com/ja/221/","markdown":"https://startupxo.com/ja/221.md","api":"https://startupxo.com/api/v1/item.json?id=221&lang=ja","text":null,"edited":null,"sources":[],"thread":[]}